CFDA, page-25

The whole dynamic changes if CFDA is granted. Most people loaded at sub $19 and just based on estimated CAGR, which will be further aided by demise of experimental products and their brands, will simply add to BAL's bullish prospects and a better CAGR than it is today. This will amplify the share price further down the track. It is very reasonable to expect a hover around $30 now.

There's so much muscles flexing BAL could do now, but I guess they're waiting for a stronger cash position.